Organic Active Ingredients TRIZ Cases

NR2B-selective NMDA antagonists target corticostriatal circuit dysfunction to reduce repetitive behavior and anxiety with fewer side effects.

Bicyclic catechol or hydroxypyridone moieties boost lactivicin uptake through bacterial iron transport, improving activity against resistant Gram-negative bacteria.

Novel amide derivatives target both RSV subtypes A and B, aiming to improve antiviral efficacy while avoiding the cost and side effects of current treatments.

Combining anti-PD-L1 antibody with anlotinib targets immune evasion and angiogenesis to reduce recurrence and drug resistance in small cell lung cancer.

A modular inhalable dendron-micelle delivers BRD4 inhibitors and peptides to fibrotic lung tissue, improving local efficacy while limiting systemic side effects.

Targeting CD38 on IgE-secreting B cells lowers total and allergen-specific IgE, helping treat IgE-mediated disease without strict allergen avoidance.

Reactive-group platinum drugs bind capture substrates through click chemistry, enabling bloodstream removal to limit off-target toxicity.

Using SWI/SNF complex loss as a biomarker predicts which cancer cells are vulnerable to GPX4 inhibition, improving treatment selectivity.

Cyclic dominant negative CSP analogs block S. pneumoniae quorum sensing to curb virulence and limit antibiotic resistance.

Sulfoalkyl ether cyclodextrin stabilizes injectable acetaminophen, limiting p-aminophenol formation without irritant buffer additives.

An amorphous nilotinib dispersion with hydrophilic polymer and surfactants boosts oral bioavailability and reduces fed-fasted absorption variation.

Combining Pertuzumab with Trastuzumab targets HER2 dimerization to extend progression-free survival while limiting cardiac toxicity.

Targeted IGF-MTX delivery inhibits MDS-related tumor growth more effectively than free MTX while avoiding treatment-induced cytopenia.

A quinuclidine GCS inhibitor restores ciliary function in Bardet-Biedl syndrome models, bypassing gene-specific therapy limits.

Selective GABA(A) alpha-2,3 partial agonists reduce Fragile X hyperexcitability and anxiety while limiting sedation and cognitive dulling.

Bradykinin receptor antagonists block pain signaling to relieve urinary bladder pain, burning, urgency, and frequency after irritation or procedures.

Pairing adagrasib with an mTOR inhibitor addresses intrinsic resistance in KRAS G12C cancers and improves efficacy consistency.

A CD20/CD3 bispecific antibody regimen treats SLE by driving B-cell lysis while minimizing cytokine release syndrome and toxicity.

PARP inhibitor maintenance extends progression-free survival in ovarian cancer after chemotherapy while avoiding repeated platinum toxicity.

Auranofin suppresses schwannoma growth at low doses, offering a safer drug option where surgery, radiation, and high-dose therapies are limited.

A selective small-molecule inhibitor suppresses 2-HG in R132 mutant IDH-1 cancers while sparing wild-type IDH-1 and mIDH-2.

Phased oral Cladribine with beta interferon balances sustained multiple sclerosis treatment benefit against adverse events and retreatment burden.

Retinoic acid pathway inhibitors reprogram the sarcoma microenvironment, boosting anti-PD1 response and long-term remission.

An antioxidant-stabilized liquid picosulfate and magnesium citrate formulation avoids stirring, prevents degradation, and supports complete dosing.

Lowering solution pH below 4.5 with a strong acid lets tranexamic acid reach much higher liquid concentrations while remaining stable.

Reducing serotonin production with tryptophan hydroxylase inhibitors helps lower tumor burden and recurrence in functional Merkel cell carcinoma.

Periodic heating and cooling of a transdermal membrane boosts diffusion on demand, enabling timed drug pulses without frequent patch replacement.

A four-strain Lactobacillus formulation helps restore vaginal flora, improve BV cure rates, and reduce recurrence after antibiotic treatment.

A porous-carrier SNEDDS tablet improves oral cannabinoid solubility and bioavailability by enabling rapid dissolution in gastric fluid.

A polymer matrix patch uses a permeation enhancer to deliver colchicine through skin, avoiding first-pass loss, GI side effects, and irritation.

Polymer dots paired with picosecond laser speed wound repair, support vascular regeneration, and help control scar formation.

Controlling HPBCD substitution patterns improves cholesterol affinity and selective solubilization without relying on broad isomer mixtures.

A pH-regulated tablet disintegrates within 60 seconds to reduce throat burning and improve nicotine uptake in the oral cavity.

Reduced-molecular-weight chondroitin sulfate oligosaccharides enable oral antihypertensive compositions that lower high blood pressure safely.

Small molecules inhibit WRN helicase to selectively kill MSI-high cancer cells while reducing damage to normal tissues.

An aqueous lidocaine, hyaluronic acid, and chondroitin sulphate composition avoids buffer irritation while maintaining pH for bladder pain relief.

Benzyl alcohol and controlled ageing keep testosterone cypionate injections crystal-free during 2-8°C storage, reducing pain on administration.

Targeting JAK-STAT inflammation with baricitinib offers a new option for treatment-resistant depression and related cognitive symptoms.

Controlled crystallization turns unstable amorphous NMNH into a low-hygroscopic crystal form suited to storage, transport, and scale-up.

A chimeric rhodopsin combines ion transport and G protein signaling to slow retinal disease progression and improve visual acuity.

A diosgenin, vitamin D, and α-lactalbumin composition targets PCOS phenotype D to regularize cycles and reduce ovarian cysts.

A selective β3-AR vibegron dose strategy treats overactive bladder while reducing antimuscarinic-like and cardiovascular side effects.

Functionalized polystyrene microspheres bind and stabilize RNA at room temperature, avoiding cryogenic storage, added protectants, and biosafety risks.

MetAP2 inhibitor combinations improve breast cancer treatment efficacy while helping mitigate hyperglycemia from PI3K-targeted therapy.

Live lactic acid bacteria with PAC and mannose help prevent recurrent UTIs by establishing protective urogenital microbiota without antibiotics.

Fitusiran uses RNA interference to suppress antithrombin, reducing bleeding episodes while avoiding the burden and inhibitor risks of factor replacement.

Covalent PTGES3 inhibitors target Cys76 to disrupt PTGES3-AR binding, suppress AR signaling, and inhibit AR-dependent prostate cancer growth.

RAFT polymer nanoparticles and DNA origami enable targeted non-viral delivery of large or multiple gene payloads with improved stability and immune evasion.

An oligonucleotide supplies missing guanine repeats to form a quadruplex on target nucleic acids that lack four native G-repeat sequences.

Prodrug SSTR4 agonists improve oral bioavailability and pain relief while reducing side effects and dependency risks in analgesic treatment.